Our laboratory is developing imaging probes labeled with diagnostic radioisotopes (RIs) for specific detection and characterization of various molecules in cancer tissues.
We also aim to develop radiopharmaceuticals labeled with therapeutic RIs with α-particles or β-particles emitters for cancers therapy.
Our approach involves the design, synthesis, and evaluation of radiopharmaceuticals specifically targeting cancer.
Our goals are to identify the novel agents for “radiotheranostics” that combine nuclear medicine diagnosis and nuclear medicine therapy which can also contribute to the personalized treatment of cancer patients.
